CRISPR Therapeutics AG (CRSP) Stock
CRSP has an Alpha Score of 23 out of 100 (poor), computed on Nov 6, 2026 from 2 of 4 sub-scores. 3 members of Congress disclosed 5 trades in CRSP since 2017: 3 purchases and 2 sales, most recently Thomas Suozzi (sale, Sep 20, 2021). Company insiders reported 0 open-market buys and 7 sales on SEC Form 4 in the 90 days to Nov 5, 2026.
What is CRSP's Alpha Score?
How it works →Alpha Score of 23 reflects poor overall profile with weak momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded CRISPR Therapeutics AG (CRSP)?
Most recent: Thomas Suozzi (sale, Sep 20, 2021); records start Oct 19, 2017.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Tom Suozzi D-NY · House | 2021-09-20 | sale | $50k – $100k |
| Tom Suozzi D-NY · House | 2021-06-03 | purchase | $50k – $100k |
| Marjorie Taylor Greene R-GA · House | 2021-01-21 | purchase | $1k – $15k |
| Jim Inhofe R-OK · Senate | 2018-06-19 | partial sale | $15k – $50k |
| Jim Inhofe R-OK · Senate | 2017-10-19 | purchase | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all CRSP political trades →Are CRISPR Therapeutics AG insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 19, 26 | Kulkarni Samarth | Chief Executive Officer | SELL | 47.8K | $2.4M |
| Oct 14, 26 | Kulkarni Samarth | Chief Executive Officer | SELL | 4.1K | $202K |
| Oct 14, 26 | Kasinger James R. | General Counsel and Secretary | SELL | 1.0K | $51K |
| Oct 14, 26 | George Simeon | Director | SELL | 14.5K | $720K |
| Oct 6, 26 | Kasinger James R. | General Counsel and Secretary | SELL | 2.0K | $119K |
| Sep 22, 26 | Kasinger James R. | General Counsel and Secretary | SELL | 10.4K | $626K |
| Sep 17, 26 | Behbahani Ali | Director | SELL | 13.7K | $781K |
SEC Form 4 filings as of Nov 5, 2026
See cluster-buy signals across all tickers →What are CRSP's key statistics?
Key statistics as of Nov 6, 2026
How does CRSP's valuation compare with the Healthcare sector?
| Metric | CRSP | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -3368.72% | 4.31% | 164 |
| Return on equity | -24.39% | 5.47% | 185 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
CRSP price chart
Powered by TradingViewWhat does CRISPR Therapeutics AG do?
CRISPR Therapeutics AG is a biopharmaceutical company specializing in gene editing therapies using its proprietary CRISPR/Cas9 platform. This revolutionary technology enables precise alteration of genomic DNA sequences to develop transformative medicines for serious diseases. The company maintains a robust portfolio of programs targeting hemoglobinopathies like sickle cell disease and beta-thalassemia with ex vivo therapies such as CASGEVY, alongside CAR T cell therapies, in vivo editing for cardiovascular conditions including CTX310 and CTX460, and type 1 diabetes. Its pipeline also advances treatments for alpha-1 antitrypsin deficiency via novel SyNTase editing and oncology applications. CRISPR Therapeutics AG focuses on both ex vivo and in vivo modalities to address unmet needs in hematology, immunology, oncology, cardiovascular, and rare genetic disorders. Founded in 2013 and headquartered in Zug, Switzerland, with key operations in Boston, the company plays a pivotal role in advancing gene-based treatments toward clinical and commercial stages in the biotechnology sector.